Selected research
Market Outlook & Growth Opportunities
Global Cell Therapy CDMO Services Market Outlook and Growth Opportunities 2026
Market perspective
The global Cell Therapy CDMO Services market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.
The North America market for Cell Therapy CDMO Services is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Cell Therapy CDMO Services is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Cell Therapy CDMO Services is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
In China, the Cell Therapy CDMO Services market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Major global companies in the Cell Therapy CDMO Services market include Thermo Fisher Scientific, Wuxi AppTec, Lonza, KBI Biopharma, RoslinCT, Cell and Gene Therapy Catapult, Cell Therapies, Minaris Regenerative Medicine and MEDINET, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.
This report provides an overview of the global Cell Therapy CDMO Services market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Cell Therapy CDMO Services and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Cell Therapy CDMO Services revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Cell Therapy CDMO Services market.
Cell Therapy CDMO Services Segment by Company
Thermo Fisher Scientific
Wuxi AppTec
Lonza
KBI Biopharma
RoslinCT
Cell and Gene Therapy Catapult
Cell Therapies
Minaris Regenerative Medicine
MEDINET
Catalent Biologics
Oxford BioMedica
GenScript
Cell-Easy
SK pharmteco
Charles River Laboratories
AGC Biologics
FUJIFILM Cellular Dynamics
Cell Therapy CDMO Services Segment by Type
Preclinical Stage
Clinical Commercialization Stage
Cell Therapy CDMO Services Segment by Application
Pharmaceutical Company
Research Institute
Cell Therapy CDMO Services Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global Cell Therapy CDMO Services status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the Cell Therapy CDMO Services key companies, revenue, market share, and recent developments.
3. To split the Cell Therapy CDMO Services breakdown data by regions, type, companies, and application.
4. To analyze the global and key regions Cell Therapy CDMO Services market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Cell Therapy CDMO Services significant trends, drivers, influence factors in global and regions.
6. To analyze Cell Therapy CDMO Services competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Cell Therapy CDMO Services market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Cell Therapy CDMO Services and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Cell Therapy CDMO Services.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Cell Therapy CDMO Services industry.
Chapter 3: Detailed analysis of Cell Therapy CDMO Services company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales value of Cell Therapy CDMO Services in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.
Chapter 7: Sales value of Cell Therapy CDMO Services in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 9: Concluding Insights.
More report detail
Tables and figures
List of Tables
Table 1. Cell Therapy CDMO Services Industry Trends
Table 2. Cell Therapy CDMO Services Industry Drivers
Table 3. Cell Therapy CDMO Services Industry Opportunities and Challenges
Table 4. Cell Therapy CDMO Services Industry Restraints
Table 5. Global Cell Therapy CDMO Services Revenue by Company (US$ Million) & (2021-2026)
Table 6. Global Cell Therapy CDMO Services Revenue Share by Company (2021-2026)
Table 7. Global Cell Therapy CDMO Services Company Ranking, (2024-2026) & (US$ Million)
Table 8. Global Cell Therapy CDMO Services Key Company Manufacturing Base & Headquarters
Table 9. Global Cell Therapy CDMO Services Company, Product Type & Application
Table 10. Global Cell Therapy CDMO Services Company Establishment Date
Table 11. Global Company Market Concentration Ratio (CR5 and HHI)
Table 12. Global Cell Therapy CDMO Services by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025)
Table 13. Mergers & Acquisitions, Expansion
Table 14. Significant Companies of Preclinical Stage
Table 15. Significant Companies of Clinical Commercialization Stage
Table 16. Global Cell Therapy CDMO Services Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million)
Table 17. Global Cell Therapy CDMO Services Sales Value by Type (2021-2026) & (US$ Million)
Table 18. Global Cell Therapy CDMO Services Sales Value by Type (2027-2032) & (US$ Million)
Table 19. Global Cell Therapy CDMO Services Sales Value Share by Type (2021-2026)
Table 20. Global Cell Therapy CDMO Services Sales Value Share by Type (2027-2032)
Table 21. Significant Companies of Pharmaceutical Company
Table 22. Significant Companies of Research Institute
Table 23. Global Cell Therapy CDMO Services Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million)
Table 24. Global Cell Therapy CDMO Services Sales Value by Application (2021-2026) & (US$ Million)
Table 25. Global Cell Therapy CDMO Services Sales Value by Application (2027-2032) & (US$ Million)
Table 26. Global Cell Therapy CDMO Services Sales Value Share by Application (2021-2026)
Table 27. Global Cell Therapy CDMO Services Sales Value Share by Application (2027-2032)
Table 28. Global Cell Therapy CDMO Services Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million)
Table 29. Global Cell Therapy CDMO Services Sales Value by Region (2021-2026) & (US$ Million)
Table 30. Global Cell Therapy CDMO Services Sales Value Share by Region (2021-2026)
Table 31. Global Cell Therapy CDMO Services Sales Value by Region (2027-2032) & (US$ Million)
Table 32. Global Cell Therapy CDMO Services Sales Value Share by Region (2027-2032)
Table 33. Global Cell Therapy CDMO Services Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million)
Table 34. Global Cell Therapy CDMO Services Sales Value by Country (2021-2026) & (US$ Million)
Table 35. Global Cell Therapy CDMO Services Sales Value Market Share by Country (2021-2026)
Table 36. Global Cell Therapy CDMO Services Sales Value by Country (2027-2032) & (US$ Million)
Table 37. Global Cell Therapy CDMO Services Sales Value Market Share by Country (2027-2032)
Table 38. Thermo Fisher Scientific Company Information
Table 39. Thermo Fisher Scientific Business Overview
Table 40. Thermo Fisher Scientific Cell Therapy CDMO Services Revenue (US$ Million) and Gross Margin (2021-2026)
Table 41. Thermo Fisher Scientific Cell Therapy CDMO Services Product Portfolio
Table 42. Thermo Fisher Scientific Recent Development
Table 43. Wuxi AppTec Company Information
Table 44. Wuxi AppTec Business Overview
Table 45. Wuxi AppTec Cell Therapy CDMO Services Revenue (US$ Million) and Gross Margin (2021-2026)
Table 46. Wuxi AppTec Cell Therapy CDMO Services Product Portfolio
Table 47. Wuxi AppTec Recent Development
Table 48. Lonza Company Information
Table 49. Lonza Business Overview
Table 50. Lonza Cell Therapy CDMO Services Revenue (US$ Million) and Gross Margin (2021-2026)
Table 51. Lonza Cell Therapy CDMO Services Product Portfolio
Table 52. Lonza Recent Development
Table 53. KBI Biopharma Company Information
Table 54. KBI Biopharma Business Overview
Table 55. KBI Biopharma Cell Therapy CDMO Services Revenue (US$ Million) and Gross Margin (2021-2026)
Table 56. KBI Biopharma Cell Therapy CDMO Services Product Portfolio
Table 57. KBI Biopharma Recent Development
Table 58. RoslinCT Company Information
Table 59. RoslinCT Business Overview
Table 60. RoslinCT Cell Therapy CDMO Services Revenue (US$ Million) and Gross Margin (2021-2026)
Table 61. RoslinCT Cell Therapy CDMO Services Product Portfolio
Table 62. RoslinCT Recent Development
Table 63. Cell and Gene Therapy Catapult Company Information
Table 64. Cell and Gene Therapy Catapult Business Overview
Table 65. Cell and Gene Therapy Catapult Cell Therapy CDMO Services Revenue (US$ Million) and Gross Margin (2021-2026)
Table 66. Cell and Gene Therapy Catapult Cell Therapy CDMO Services Product Portfolio
Table 67. Cell and Gene Therapy Catapult Recent Development
Table 68. Cell Therapies Company Information
Table 69. Cell Therapies Business Overview
Table 70. Cell Therapies Cell Therapy CDMO Services Revenue (US$ Million) and Gross Margin (2021-2026)
Table 71. Cell Therapies Cell Therapy CDMO Services Product Portfolio
Table 72. Cell Therapies Recent Development
Table 73. Minaris Regenerative Medicine Company Information
Table 74. Minaris Regenerative Medicine Business Overview
Table 75. Minaris Regenerative Medicine Cell Therapy CDMO Services Revenue (US$ Million) and Gross Margin (2021-2026)
Table 76. Minaris Regenerative Medicine Cell Therapy CDMO Services Product Portfolio
Table 77. Minaris Regenerative Medicine Recent Development
Table 78. MEDINET Company Information
Table 79. MEDINET Business Overview
Table 80. MEDINET Cell Therapy CDMO Services Revenue (US$ Million) and Gross Margin (2021-2026)
Table 81. MEDINET Cell Therapy CDMO Services Product Portfolio
Table 82. MEDINET Recent Development
Table 83. Catalent Biologics Company Information
Table 84. Catalent Biologics Business Overview
Table 85. Catalent Biologics Cell Therapy CDMO Services Revenue (US$ Million) and Gross Margin (2021-2026)
Table 86. Catalent Biologics Cell Therapy CDMO Services Product Portfolio
Table 87. Catalent Biologics Recent Development
Table 88. Oxford BioMedica Company Information
Table 89. Oxford BioMedica Business Overview
Table 90. Oxford BioMedica Cell Therapy CDMO Services Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026)
Table 91. Oxford BioMedica Cell Therapy CDMO Services Product Portfolio
Table 92. Oxford BioMedica Recent Development
Table 93. GenScript Company Information
Table 94. GenScript Business Overview
Table 95. GenScript Cell Therapy CDMO Services Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026)
Table 96. GenScript Cell Therapy CDMO Services Product Portfolio
Table 97. GenScript Recent Development
Table 98. Cell-Easy Company Information
Table 99. Cell-Easy Business Overview
Table 100. Cell-Easy Cell Therapy CDMO Services Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026)
Table 101. Cell-Easy Cell Therapy CDMO Services Product Portfolio
Table 102. Cell-Easy Recent Development
Table 103. SK pharmteco Company Information
Table 104. SK pharmteco Business Overview
Table 105. SK pharmteco Cell Therapy CDMO Services Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026)
Table 106. SK pharmteco Cell Therapy CDMO Services Product Portfolio
Table 107. SK pharmteco Recent Development
Table 108. Charles River Laboratories Company Information
Table 109. Charles River Laboratories Business Overview
Table 110. Charles River Laboratories Cell Therapy CDMO Services Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026)
Table 111. Charles River Laboratories Cell Therapy CDMO Services Product Portfolio
Table 112. Charles River Laboratories Recent Development
Table 113. AGC Biologics Company Information
Table 114. AGC Biologics Business Overview
Table 115. AGC Biologics Cell Therapy CDMO Services Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026)
Table 116. AGC Biologics Cell Therapy CDMO Services Product Portfolio
Table 117. AGC Biologics Recent Development
Table 118. FUJIFILM Cellular Dynamics Company Information
Table 119. FUJIFILM Cellular Dynamics Business Overview
Table 120. FUJIFILM Cellular Dynamics Cell Therapy CDMO Services Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026)
Table 121. FUJIFILM Cellular Dynamics Cell Therapy CDMO Services Product Portfolio
Table 122. FUJIFILM Cellular Dynamics Recent Development
Table 123. Research Programs/Design for This Report
Table 124. Authors List of This Report
Table 125. Secondary Sources
Table 126. Primary Sources
List of Figures
Figure 1. Cell Therapy CDMO Services Product Image
Figure 2. Global Cell Therapy CDMO Services Market Size (US$ Million), 2021 VS 2025 VS 2032
Figure 3. Global Cell Therapy CDMO Services Market Size (2021-2032) & (US$ Million)
Figure 4. Global Cell Therapy CDMO Services Company Revenue Ranking in 2025 (US$ Million)
Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million)
Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025
Figure 7. Preclinical Stage Image
Figure 8. Clinical Commercialization Stage Image
Figure 9. Global Cell Therapy CDMO Services Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million)
Figure 10. Global Cell Therapy CDMO Services Sales Value Share 2021 VS 2025 VS 2032
Figure 11. Global Cell Therapy CDMO Services Sales Value Share by Type (2021-2032)
Figure 12. Pharmaceutical Company Image
Figure 13. Research Institute Image
Figure 14. Global Cell Therapy CDMO Services Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million)
Figure 15. Global Cell Therapy CDMO Services Sales Value Share 2021 VS 2025 VS 2032
Figure 16. Global Cell Therapy CDMO Services Sales Value Share by Application (2021-2032)
Figure 17. Global Cell Therapy CDMO Services Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million)
Figure 18. Global Cell Therapy CDMO Services Sales Value Share by Region: 2021 VS 2025 VS 2032
Figure 19. North America Cell Therapy CDMO Services Sales Value (2021-2032) & (US$ Million)
Figure 20. North America Cell Therapy CDMO Services Sales Value Share by Country (%), 2025 VS 2032
Figure 21. Europe Cell Therapy CDMO Services Sales Value (2021-2032) & (US$ Million)
Figure 22. Europe Cell Therapy CDMO Services Sales Value Share by Country (%), 2025 VS 2032
Figure 23. Asia-Pacific Cell Therapy CDMO Services Sales Value (2021-2032) & (US$ Million)
Figure 24. Asia-Pacific Cell Therapy CDMO Services Sales Value Share by Country (%), 2025 VS 2032
Figure 25. South America Cell Therapy CDMO Services Sales Value (2021-2032) & (US$ Million)
Figure 26. South America Cell Therapy CDMO Services Sales Value Share by Country (%), 2025 VS 2032
Figure 27. Middle East & Africa Cell Therapy CDMO Services Sales Value (2021-2032) & (US$ Million)
Figure 28. Middle East & Africa Cell Therapy CDMO Services Sales Value Share by Country (%), 2025 VS 2032
Figure 29. USA Cell Therapy CDMO Services Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 30. USA Cell Therapy CDMO Services Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 31. USA Cell Therapy CDMO Services Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 32. Canada Cell Therapy CDMO Services Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 33. Canada Cell Therapy CDMO Services Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 34. Canada Cell Therapy CDMO Services Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 35. Mexico Cell Therapy CDMO Services Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 36. Mexico Cell Therapy CDMO Services Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 37. Mexico Cell Therapy CDMO Services Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 38. Germany Cell Therapy CDMO Services Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 39. Germany Cell Therapy CDMO Services Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 40. Germany Cell Therapy CDMO Services Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 41. France Cell Therapy CDMO Services Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 42. France Cell Therapy CDMO Services Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 43. France Cell Therapy CDMO Services Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 44. U.K. Cell Therapy CDMO Services Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 45. U.K. Cell Therapy CDMO Services Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 46. U.K. Cell Therapy CDMO Services Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 47. Italy Cell Therapy CDMO Services Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 48. Italy Cell Therapy CDMO Services Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 49. Italy Cell Therapy CDMO Services Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 50. Spain Cell Therapy CDMO Services Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 51. Spain Cell Therapy CDMO Services Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 52. Spain Cell Therapy CDMO Services Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 53. Russia Cell Therapy CDMO Services Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 54. Russia Cell Therapy CDMO Services Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 55. Russia Cell Therapy CDMO Services Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 56. Netherlands Cell Therapy CDMO Services Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 57. Netherlands Cell Therapy CDMO Services Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 58. Netherlands Cell Therapy CDMO Services Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 59. Nordic Countries Cell Therapy CDMO Services Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 60. Nordic Countries Cell Therapy CDMO Services Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 61. Nordic Countries Cell Therapy CDMO Services Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 62. China Cell Therapy CDMO Services Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 63. China Cell Therapy CDMO Services Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 64. China Cell Therapy CDMO Services Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 65. Japan Cell Therapy CDMO Services Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 66. Japan Cell Therapy CDMO Services Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 67. Japan Cell Therapy CDMO Services Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 68. South Korea Cell Therapy CDMO Services Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 69. South Korea Cell Therapy CDMO Services Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 70. South Korea Cell Therapy CDMO Services Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 71. India Cell Therapy CDMO Services Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 72. India Cell Therapy CDMO Services Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 73. India Cell Therapy CDMO Services Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 74. Australia Cell Therapy CDMO Services Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 75. Australia Cell Therapy CDMO Services Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 76. Australia Cell Therapy CDMO Services Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 77. Southeast Asia Cell Therapy CDMO Services Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 78. Southeast Asia Cell Therapy CDMO Services Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 79. Southeast Asia Cell Therapy CDMO Services Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 80. Brazil Cell Therapy CDMO Services Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 81. Brazil Cell Therapy CDMO Services Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 82. Brazil Cell Therapy CDMO Services Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 83. Argentina Cell Therapy CDMO Services Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 84. Argentina Cell Therapy CDMO Services Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 85. Argentina Cell Therapy CDMO Services Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 86. Chile Cell Therapy CDMO Services Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 87. Chile Cell Therapy CDMO Services Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 88. Chile Cell Therapy CDMO Services Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 89. Colombia Cell Therapy CDMO Services Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 90. Colombia Cell Therapy CDMO Services Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 91. Colombia Cell Therapy CDMO Services Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 92. Peru Cell Therapy CDMO Services Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 93. Peru Cell Therapy CDMO Services Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 94. Peru Cell Therapy CDMO Services Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 95. Saudi Arabia Cell Therapy CDMO Services Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 96. Saudi Arabia Cell Therapy CDMO Services Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 97. Saudi Arabia Cell Therapy CDMO Services Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 98. Israel Cell Therapy CDMO Services Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 99. Israel Cell Therapy CDMO Services Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 100. Israel Cell Therapy CDMO Services Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 101. UAE Cell Therapy CDMO Services Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 102. UAE Cell Therapy CDMO Services Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 103. UAE Cell Therapy CDMO Services Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 104. Turkey Cell Therapy CDMO Services Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 105. Turkey Cell Therapy CDMO Services Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 106. Turkey Cell Therapy CDMO Services Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 107. Iran Cell Therapy CDMO Services Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 108. Iran Cell Therapy CDMO Services Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 109. Iran Cell Therapy CDMO Services Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 110. Egypt Cell Therapy CDMO Services Sales Value Growth Rate (2021-2032) & (US$ Million)
Figure 111. Egypt Cell Therapy CDMO Services Sales Value Share by Type, 2025 VS 2032 & (%)
Figure 112. Egypt Cell Therapy CDMO Services Sales Value Share by Application, 2025 VS 2032 & (%)
Figure 113. Years Considered
Figure 114. Research Process
Figure 115. Key Executives Interviewed
Scope & coverage.
Types
- Preclinical Stage
- Clinical Commercialization Stage
Applications
- Pharmaceutical Company
- Research Institute
Companies covered
- Thermo Fisher Scientific
- Wuxi AppTec
- Lonza
- KBI Biopharma
- RoslinCT
- Cell and Gene Therapy Catapult
- Cell Therapies
- Minaris Regenerative Medicine
- MEDINET
- Catalent Biologics
- Oxford BioMedica
- GenScript
- Cell-Easy
- SK pharmteco
- Charles River Laboratories
- AGC Biologics
- FUJIFILM Cellular Dynamics
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Cell Therapy CDMO Services Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Cell Therapy CDMO Services Market Size (2021-2032)
- 1.4 Assumptions and Limitations
- 1.5 Study Goals and Objectives
2 Cell Therapy CDMO Services Market Dynamics
- 2.1 Cell Therapy CDMO Services Industry Trends
- 2.2 Cell Therapy CDMO Services Industry Drivers
- 2.3 Cell Therapy CDMO Services Industry Opportunities and Challenges
- 2.4 Cell Therapy CDMO Services Industry Restraints
3 Cell Therapy CDMO Services Market by Company
- 3.1 Global Cell Therapy CDMO Services Company Revenue Ranking in 2025
- 3.2 Global Cell Therapy CDMO Services Revenue by Company (2021-2026)
- 3.3 Global Cell Therapy CDMO Services Company Ranking (2024-2026)
- 3.4 Global Cell Therapy CDMO Services Company Manufacturing Base and Headquarters
- 3.5 Global Cell Therapy CDMO Services Company Product Type and Application
- 3.6 Global Cell Therapy CDMO Services Company Establishment Date
- 3.7 Market Competitive Analysis
- 3.7.1 Global Cell Therapy CDMO Services Market Concentration Ratio (CR5 and HHI)
- 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
- 3.7.3 2025 Cell Therapy CDMO Services Tier 1, Tier 2, and Tier 3 Companies
- 3.8 Mergers and Acquisitions Expansion
4 Cell Therapy CDMO Services Market by Type
- 4.1 Cell Therapy CDMO Services Type Introduction
- 4.1.1 Preclinical Stage
- 4.1.2 Clinical Commercialization Stage
- 4.2 Global Cell Therapy CDMO Services Sales Value by Type
- 4.2.1 Global Cell Therapy CDMO Services Sales Value by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Cell Therapy CDMO Services Sales Value by Type (2021-2032)
- 4.2.3 Global Cell Therapy CDMO Services Sales Value Share by Type (2021-2032)
5 Cell Therapy CDMO Services Market by Application
- 5.1 Cell Therapy CDMO Services Application Introduction
- 5.1.1 Pharmaceutical Company
- 5.1.2 Research Institute
- 5.2 Global Cell Therapy CDMO Services Sales Value by Application
- 5.2.1 Global Cell Therapy CDMO Services Sales Value by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Cell Therapy CDMO Services Sales Value by Application (2021-2032)
- 5.2.3 Global Cell Therapy CDMO Services Sales Value Share by Application (2021-2032)
6 Cell Therapy CDMO Services Regional Value Analysis
- 6.1 Global Cell Therapy CDMO Services Sales Value by Region: 2021 VS 2025 VS 2032
- 6.2 Global Cell Therapy CDMO Services Sales Value by Region (2021-2032)
- 6.2.1 Global Cell Therapy CDMO Services Sales Value by Region: 2021-2026
- 6.2.2 Global Cell Therapy CDMO Services Sales Value by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Cell Therapy CDMO Services Sales Value (2021-2032)
- 6.3.2 North America Cell Therapy CDMO Services Sales Value Share by Country, 2025 VS 2032
- 6.4 Europe
- 6.4.1 Europe Cell Therapy CDMO Services Sales Value (2021-2032)
- 6.4.2 Europe Cell Therapy CDMO Services Sales Value Share by Country, 2025 VS 2032
- 6.5 Asia-Pacific
- 6.5.1 Asia-Pacific Cell Therapy CDMO Services Sales Value (2021-2032)
- 6.5.2 Asia-Pacific Cell Therapy CDMO Services Sales Value Share by Country, 2025 VS 2032
- 6.6 South America
- 6.6.1 South America Cell Therapy CDMO Services Sales Value (2021-2032)
- 6.6.2 South America Cell Therapy CDMO Services Sales Value Share by Country, 2025 VS 2032
- 6.7 Middle East & Africa
- 6.7.1 Middle East & Africa Cell Therapy CDMO Services Sales Value (2021-2032)
- 6.7.2 Middle East & Africa Cell Therapy CDMO Services Sales Value Share by Country, 2025 VS 2032
7 Cell Therapy CDMO Services Country-level Value Analysis
- 7.1 Global Cell Therapy CDMO Services Sales Value by Country: 2021 VS 2025 VS 2032
- 7.2 Global Cell Therapy CDMO Services Sales Value by Country (2021-2032)
- 7.2.1 Global Cell Therapy CDMO Services Sales Value by Country (2021-2026)
- 7.2.2 Global Cell Therapy CDMO Services Sales Value by Country (2027-2032)
- 7.3 USA
- 7.3.1 USA Cell Therapy CDMO Services Sales Value Growth Rate (2021-2032)
- 7.3.2 USA Cell Therapy CDMO Services Sales Value Share by Type, 2025 VS 2032
- 7.3.3 USA Cell Therapy CDMO Services Sales Value Share by Application, 2025 VS 2032
- 7.4 Canada
- 7.4.1 Canada Cell Therapy CDMO Services Sales Value Growth Rate (2021-2032)
- 7.4.2 Canada Cell Therapy CDMO Services Sales Value Share by Type, 2025 VS 2032
- 7.4.3 Canada Cell Therapy CDMO Services Sales Value Share by Application, 2025 VS 2032
- 7.5 Mexico
- 7.5.1 Mexico Cell Therapy CDMO Services Sales Value Growth Rate (2021-2032)
- 7.5.2 Mexico Cell Therapy CDMO Services Sales Value Share by Type, 2025 VS 2032
- 7.5.3 Mexico Cell Therapy CDMO Services Sales Value Share by Application, 2025 VS 2032
- 7.6 Germany
- 7.6.1 Germany Cell Therapy CDMO Services Sales Value Growth Rate (2021-2032)
- 7.6.2 Germany Cell Therapy CDMO Services Sales Value Share by Type, 2025 VS 2032
- 7.6.3 Germany Cell Therapy CDMO Services Sales Value Share by Application, 2025 VS 2032
- 7.7 France
- 7.7.1 France Cell Therapy CDMO Services Sales Value Growth Rate (2021-2032)
- 7.7.2 France Cell Therapy CDMO Services Sales Value Share by Type, 2025 VS 2032
- 7.7.3 France Cell Therapy CDMO Services Sales Value Share by Application, 2025 VS 2032
- 7.8 U.K.
- 7.8.1 U.K. Cell Therapy CDMO Services Sales Value Growth Rate (2021-2032)
- 7.8.2 U.K. Cell Therapy CDMO Services Sales Value Share by Type, 2025 VS 2032
- 7.8.3 U.K. Cell Therapy CDMO Services Sales Value Share by Application, 2025 VS 2032
- 7.9 Italy
- 7.9.1 Italy Cell Therapy CDMO Services Sales Value Growth Rate (2021-2032)
- 7.9.2 Italy Cell Therapy CDMO Services Sales Value Share by Type, 2025 VS 2032
- 7.9.3 Italy Cell Therapy CDMO Services Sales Value Share by Application, 2025 VS 2032
- 7.10 Spain
- 7.10.1 Spain Cell Therapy CDMO Services Sales Value Growth Rate (2021-2032)
- 7.10.2 Spain Cell Therapy CDMO Services Sales Value Share by Type, 2025 VS 2032
- 7.10.3 Spain Cell Therapy CDMO Services Sales Value Share by Application, 2025 VS 2032
- 7.11 Russia
- 7.11.1 Russia Cell Therapy CDMO Services Sales Value Growth Rate (2021-2032)
- 7.11.2 Russia Cell Therapy CDMO Services Sales Value Share by Type, 2025 VS 2032
- 7.11.3 Russia Cell Therapy CDMO Services Sales Value Share by Application, 2025 VS 2032
- 7.12 Netherlands
- 7.12.1 Netherlands Cell Therapy CDMO Services Sales Value Growth Rate (2021-2032)
- 7.12.2 Netherlands Cell Therapy CDMO Services Sales Value Share by Type, 2025 VS 2032
- 7.12.3 Netherlands Cell Therapy CDMO Services Sales Value Share by Application, 2025 VS 2032
- 7.13 Nordic Countries
- 7.13.1 Nordic Countries Cell Therapy CDMO Services Sales Value Growth Rate (2021-2032)
- 7.13.2 Nordic Countries Cell Therapy CDMO Services Sales Value Share by Type, 2025 VS 2032
- 7.13.3 Nordic Countries Cell Therapy CDMO Services Sales Value Share by Application, 2025 VS 2032
- 7.14 China
- 7.14.1 China Cell Therapy CDMO Services Sales Value Growth Rate (2021-2032)
- 7.14.2 China Cell Therapy CDMO Services Sales Value Share by Type, 2025 VS 2032
- 7.14.3 China Cell Therapy CDMO Services Sales Value Share by Application, 2025 VS 2032
- 7.15 Japan
- 7.15.1 Japan Cell Therapy CDMO Services Sales Value Growth Rate (2021-2032)
- 7.15.2 Japan Cell Therapy CDMO Services Sales Value Share by Type, 2025 VS 2032
- 7.15.3 Japan Cell Therapy CDMO Services Sales Value Share by Application, 2025 VS 2032
- 7.16 South Korea
- 7.16.1 South Korea Cell Therapy CDMO Services Sales Value Growth Rate (2021-2032)
- 7.16.2 South Korea Cell Therapy CDMO Services Sales Value Share by Type, 2025 VS 2032
- 7.16.3 South Korea Cell Therapy CDMO Services Sales Value Share by Application, 2025 VS 2032
- 7.17 India
- 7.17.1 India Cell Therapy CDMO Services Sales Value Growth Rate (2021-2032)
- 7.17.2 India Cell Therapy CDMO Services Sales Value Share by Type, 2025 VS 2032
- 7.17.3 India Cell Therapy CDMO Services Sales Value Share by Application, 2025 VS 2032
- 7.18 Australia
- 7.18.1 Australia Cell Therapy CDMO Services Sales Value Growth Rate (2021-2032)
- 7.18.2 Australia Cell Therapy CDMO Services Sales Value Share by Type, 2025 VS 2032
- 7.18.3 Australia Cell Therapy CDMO Services Sales Value Share by Application, 2025 VS 2032
- 7.19 Southeast Asia
- 7.19.1 Southeast Asia Cell Therapy CDMO Services Sales Value Growth Rate (2021-2032)
- 7.19.2 Southeast Asia Cell Therapy CDMO Services Sales Value Share by Type, 2025 VS 2032
- 7.19.3 Southeast Asia Cell Therapy CDMO Services Sales Value Share by Application, 2025 VS 2032
- 7.20 Brazil
- 7.20.1 Brazil Cell Therapy CDMO Services Sales Value Growth Rate (2021-2032)
- 7.20.2 Brazil Cell Therapy CDMO Services Sales Value Share by Type, 2025 VS 2032
- 7.20.3 Brazil Cell Therapy CDMO Services Sales Value Share by Application, 2025 VS 2032
- 7.21 Argentina
- 7.21.1 Argentina Cell Therapy CDMO Services Sales Value Growth Rate (2021-2032)
- 7.21.2 Argentina Cell Therapy CDMO Services Sales Value Share by Type, 2025 VS 2032
- 7.21.3 Argentina Cell Therapy CDMO Services Sales Value Share by Application, 2025 VS 2032
- 7.22 Chile
- 7.22.1 Chile Cell Therapy CDMO Services Sales Value Growth Rate (2021-2032)
- 7.22.2 Chile Cell Therapy CDMO Services Sales Value Share by Type, 2025 VS 2032
- 7.22.3 Chile Cell Therapy CDMO Services Sales Value Share by Application, 2025 VS 2032
- 7.23 Colombia
- 7.23.1 Colombia Cell Therapy CDMO Services Sales Value Growth Rate (2021-2032)
- 7.23.2 Colombia Cell Therapy CDMO Services Sales Value Share by Type, 2025 VS 2032
- 7.23.3 Colombia Cell Therapy CDMO Services Sales Value Share by Application, 2025 VS 2032
- 7.24 Peru
- 7.24.1 Peru Cell Therapy CDMO Services Sales Value Growth Rate (2021-2032)
- 7.24.2 Peru Cell Therapy CDMO Services Sales Value Share by Type, 2025 VS 2032
- 7.24.3 Peru Cell Therapy CDMO Services Sales Value Share by Application, 2025 VS 2032
- 7.25 Saudi Arabia
- 7.25.1 Saudi Arabia Cell Therapy CDMO Services Sales Value Growth Rate (2021-2032)
- 7.25.2 Saudi Arabia Cell Therapy CDMO Services Sales Value Share by Type, 2025 VS 2032
- 7.25.3 Saudi Arabia Cell Therapy CDMO Services Sales Value Share by Application, 2025 VS 2032
- 7.26 Israel
- 7.26.1 Israel Cell Therapy CDMO Services Sales Value Growth Rate (2021-2032)
- 7.26.2 Israel Cell Therapy CDMO Services Sales Value Share by Type, 2025 VS 2032
- 7.26.3 Israel Cell Therapy CDMO Services Sales Value Share by Application, 2025 VS 2032
- 7.27 UAE
- 7.27.1 UAE Cell Therapy CDMO Services Sales Value Growth Rate (2021-2032)
- 7.27.2 UAE Cell Therapy CDMO Services Sales Value Share by Type, 2025 VS 2032
- 7.27.3 UAE Cell Therapy CDMO Services Sales Value Share by Application, 2025 VS 2032
- 7.28 Turkey
- 7.28.1 Turkey Cell Therapy CDMO Services Sales Value Growth Rate (2021-2032)
- 7.28.2 Turkey Cell Therapy CDMO Services Sales Value Share by Type, 2025 VS 2032
- 7.28.3 Turkey Cell Therapy CDMO Services Sales Value Share by Application, 2025 VS 2032
- 7.29 Iran
- 7.29.1 Iran Cell Therapy CDMO Services Sales Value Growth Rate (2021-2032)
- 7.29.2 Iran Cell Therapy CDMO Services Sales Value Share by Type, 2025 VS 2032
- 7.29.3 Iran Cell Therapy CDMO Services Sales Value Share by Application, 2025 VS 2032
- 7.30 Egypt
- 7.30.1 Egypt Cell Therapy CDMO Services Sales Value Growth Rate (2021-2032)
- 7.30.2 Egypt Cell Therapy CDMO Services Sales Value Share by Type, 2025 VS 2032
- 7.30.3 Egypt Cell Therapy CDMO Services Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
- 8.1 Thermo Fisher Scientific
- 8.1.1 Thermo Fisher Scientific Company Information
- 8.1.2 Thermo Fisher Scientific Business Overview
- 8.1.3 Thermo Fisher Scientific Cell Therapy CDMO Services Revenue and Gross Margin (2021-2026)
- 8.1.4 Thermo Fisher Scientific Cell Therapy CDMO Services Product Portfolio
- 8.1.5 Thermo Fisher Scientific Recent Developments
- 8.2 Wuxi AppTec
- 8.2.1 Wuxi AppTec Company Information
- 8.2.2 Wuxi AppTec Business Overview
- 8.2.3 Wuxi AppTec Cell Therapy CDMO Services Revenue and Gross Margin (2021-2026)
- 8.2.4 Wuxi AppTec Cell Therapy CDMO Services Product Portfolio
- 8.2.5 Wuxi AppTec Recent Developments
- 8.3 Lonza
- 8.3.1 Lonza Company Information
- 8.3.2 Lonza Business Overview
- 8.3.3 Lonza Cell Therapy CDMO Services Revenue and Gross Margin (2021-2026)
- 8.3.4 Lonza Cell Therapy CDMO Services Product Portfolio
- 8.3.5 Lonza Recent Developments
- 8.4 KBI Biopharma
- 8.4.1 KBI Biopharma Company Information
- 8.4.2 KBI Biopharma Business Overview
- 8.4.3 KBI Biopharma Cell Therapy CDMO Services Revenue and Gross Margin (2021-2026)
- 8.4.4 KBI Biopharma Cell Therapy CDMO Services Product Portfolio
- 8.4.5 KBI Biopharma Recent Developments
- 8.5 RoslinCT
- 8.5.1 RoslinCT Company Information
- 8.5.2 RoslinCT Business Overview
- 8.5.3 RoslinCT Cell Therapy CDMO Services Revenue and Gross Margin (2021-2026)
- 8.5.4 RoslinCT Cell Therapy CDMO Services Product Portfolio
- 8.5.5 RoslinCT Recent Developments
- 8.6 Cell and Gene Therapy Catapult
- 8.6.1 Cell and Gene Therapy Catapult Company Information
- 8.6.2 Cell and Gene Therapy Catapult Business Overview
- 8.6.3 Cell and Gene Therapy Catapult Cell Therapy CDMO Services Revenue and Gross Margin (2021-2026)
- 8.6.4 Cell and Gene Therapy Catapult Cell Therapy CDMO Services Product Portfolio
- 8.6.5 Cell and Gene Therapy Catapult Recent Developments
- 8.7 Cell Therapies
- 8.7.1 Cell Therapies Company Information
- 8.7.2 Cell Therapies Business Overview
- 8.7.3 Cell Therapies Cell Therapy CDMO Services Revenue and Gross Margin (2021-2026)
- 8.7.4 Cell Therapies Cell Therapy CDMO Services Product Portfolio
- 8.7.5 Cell Therapies Recent Developments
- 8.8 Minaris Regenerative Medicine
- 8.8.1 Minaris Regenerative Medicine Company Information
- 8.8.2 Minaris Regenerative Medicine Business Overview
- 8.8.3 Minaris Regenerative Medicine Cell Therapy CDMO Services Revenue and Gross Margin (2021-2026)
- 8.8.4 Minaris Regenerative Medicine Cell Therapy CDMO Services Product Portfolio
- 8.8.5 Minaris Regenerative Medicine Recent Developments
- 8.9 MEDINET
- 8.9.1 MEDINET Company Information
- 8.9.2 MEDINET Business Overview
- 8.9.3 MEDINET Cell Therapy CDMO Services Revenue and Gross Margin (2021-2026)
- 8.9.4 MEDINET Cell Therapy CDMO Services Product Portfolio
- 8.9.5 MEDINET Recent Developments
- 8.10 Catalent Biologics
- 8.10.1 Catalent Biologics Company Information
- 8.10.2 Catalent Biologics Business Overview
- 8.10.3 Catalent Biologics Cell Therapy CDMO Services Revenue and Gross Margin (2021-2026)
- 8.10.4 Catalent Biologics Cell Therapy CDMO Services Product Portfolio
- 8.10.5 Catalent Biologics Recent Developments
- 8.11 Oxford BioMedica
- 8.11.1 Oxford BioMedica Company Information
- 8.11.2 Oxford BioMedica Business Overview
- 8.11.3 Oxford BioMedica Cell Therapy CDMO Services Revenue and Gross Margin (2021-2026)
- 8.11.4 Oxford BioMedica Cell Therapy CDMO Services Product Portfolio
- 8.11.5 Oxford BioMedica Recent Developments
- 8.12 GenScript
- 8.12.1 GenScript Company Information
- 8.12.2 GenScript Business Overview
- 8.12.3 GenScript Cell Therapy CDMO Services Revenue and Gross Margin (2021-2026)
- 8.12.4 GenScript Cell Therapy CDMO Services Product Portfolio
- 8.12.5 GenScript Recent Developments
- 8.13 Cell-Easy
- 8.13.1 Cell-Easy Company Information
- 8.13.2 Cell-Easy Business Overview
- 8.13.3 Cell-Easy Cell Therapy CDMO Services Revenue and Gross Margin (2021-2026)
- 8.13.4 Cell-Easy Cell Therapy CDMO Services Product Portfolio
- 8.13.5 Cell-Easy Recent Developments
- 8.14 SK pharmteco
- 8.14.1 SK pharmteco Company Information
- 8.14.2 SK pharmteco Business Overview
- 8.14.3 SK pharmteco Cell Therapy CDMO Services Revenue and Gross Margin (2021-2026)
- 8.14.4 SK pharmteco Cell Therapy CDMO Services Product Portfolio
- 8.14.5 SK pharmteco Recent Developments
- 8.15 Charles River Laboratories
- 8.15.1 Charles River Laboratories Company Information
- 8.15.2 Charles River Laboratories Business Overview
- 8.15.3 Charles River Laboratories Cell Therapy CDMO Services Revenue and Gross Margin (2021-2026)
- 8.15.4 Charles River Laboratories Cell Therapy CDMO Services Product Portfolio
- 8.15.5 Charles River Laboratories Recent Developments
- 8.16 AGC Biologics
- 8.16.1 AGC Biologics Company Information
- 8.16.2 AGC Biologics Business Overview
- 8.16.3 AGC Biologics Cell Therapy CDMO Services Revenue and Gross Margin (2021-2026)
- 8.16.4 AGC Biologics Cell Therapy CDMO Services Product Portfolio
- 8.16.5 AGC Biologics Recent Developments
- 8.17 FUJIFILM Cellular Dynamics
- 8.17.1 FUJIFILM Cellular Dynamics Company Information
- 8.17.2 FUJIFILM Cellular Dynamics Business Overview
- 8.17.3 FUJIFILM Cellular Dynamics Cell Therapy CDMO Services Revenue and Gross Margin (2021-2026)
- 8.17.4 FUJIFILM Cellular Dynamics Cell Therapy CDMO Services Product Portfolio
- 8.17.5 FUJIFILM Cellular Dynamics Recent Developments
9 Concluding Insights
10 Appendix
- 10.1 Reasons for Doing This Study
- 10.2 Research Methodology
- 10.3 Research Process
- 10.4 Authors List of This Report
- 10.5 Data Source
- 10.5.1 Secondary Sources
- 10.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
$4,250USD
Buy nowPDF by email within 3–5 working days after payment confirmation.
Talk to an analyst